其二，上市公司需主动搭建高效的价值传递通道，核心在于信息的公开透明与精准触达。一方面，企业 应恪守监管要求，将经营数据、战略规划、风险提示等核心信息主动、及时、完整地披露，杜绝选择性 披露或信息滞后问题，以透明度消除市场信息不对称，夯实投资者信任基础；另一方面，企业可以突破 传统公告披露的单一模式，通过业绩说明会、投资者调研、行业峰会等多元化场景，用更通俗化的语言 解读专业财务信息，用更具象化的案例传递企业核心竞争力，让品牌价值不仅停留在财报数据中，更能 被市场直观感知。 其三，品牌价值本质是市场信任的积累，上市公司需从多维度构建信任溢价。在公司治理层面，要完善 治理结构、保持决策透明，通过清晰的长期战略规划稳定投资者预期；在社会责任层面，需重视ESG管 理与披露，积极履行环保、公益等责任，吸引长期价值投资者；在风险应对层面，要建立危机公关快速 反应机制，面对负面事件时坦诚沟通，最大限度挽回市场信任。 值得关注的是，上市公司作为品牌价值管理的第一责任主体，肩负着核心推进职责，但这一系统工程的 落地见效，同样离不开监管体系的优化完善与正向引导。沪深交易所于今年3月份对上市公司自律监管 指引中的重大资产重组部分进 ...

Group 1: Financial Performance - The company achieved a revenue of 2.504 billion yuan in the first half of 2025, representing a year-on-year growth of 15.52% [3] - The net profit attributable to shareholders was 104 million yuan, with a year-on-year increase of 42.17% [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 101 million yuan, showing a growth of 43.28% year-on-year [3] Group 2: Goodwill Management - The company reported a goodwill amount of 1.354 billion yuan, raising concerns about potential risks [2] - Measures have been implemented to control and reduce risks associated with goodwill, including a focus on core business and strategic acquisitions [2][3] - Regular impairment testing of goodwill is conducted to monitor and evaluate factors that may affect its value [3] Group 3: Stock Performance and Market Perception - The company's stock price has been underperforming, influenced by macroeconomic conditions, industry dynamics, and market sentiment [3][4] - Management emphasizes that strong performance is essential for enhancing market value and shareholder returns [3] - The company is committed to improving operational efficiency and innovation to create long-term value for shareholders [3] Group 4: Strategic Focus and Future Plans - The company adheres to a "1234 development strategy," focusing on the pharmaceutical retail sector and enhancing core competitiveness [4] - Future plans include deepening engagement in the pharmaceutical field and exploring opportunities in AI and smart technologies [6][7] - The company aims to create a balanced and synergistic pharmaceutical ecosystem, transitioning from single pharmaceutical sales to comprehensive health services [4]